glp-1 news today 2025-10-16 Weight-Loss Drug Demonstration Begins July 2026 Alarming rise in weight loss

Since 2008, our law firm has secured numerous multi-million dollar verdicts in large complex lawsuits

Tirzepatide (Mounjaro) Technically a dual GIP/GLP-1 receptor agonist, meaning it targets two incretin hormones rather than one

Vegans or people with certain genetic problems may not be able to produce sufficient amounts of carnitine themselves or ingest them from external sources

Without a doctor or medical professional coaching you through long-term treatment, he says you risk possible negative interactions with medications youre already taking or worsening renal function, gallbladder disease, or pancreatitis

Each has different ingredient profiles and varying levels of evidence

JAMA 305 (21), 21842192